Ranjana H Advani

6PUBLICATIONS
38CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMedical virologyMedical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 12, 2024
Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma.

Joseph G Schroers-Martin, Ranjana Advani

|Mar 27, 2024
Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project.

Monica Civallero, Joseph G Schroers-Martin, Steven Horwitz

|Nov 18, 2021
Venetoclax in Previously Treated Waldenström Macroglobulinemia.

Jorge J Castillo, John N Allan, Tanya Siddiqi

|Apr 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.

Anita Kumar, Carla Casulo, Ranjana H Advani

|Nov 18, 2020
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.

Jorge J Castillo, Jithma P Abeykoon, Joshua N Gustine

|Sep 15, 2020
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.

Steven P Treon, Kirsten Meid, Joshua Gustine

Pageof 1

Frequent Collaborators

3 joint publications

Steven P Treon

3 joint publications

Zachary R Hunter

3 joint publications

Maria Lia Palomba

3 joint publications

Jorge J Castillo